Halo-substituted active methylene compounds

Details Halo-substituted active methylene compounds Halo-substituted active methylene compounds

2007-02-20

2007-02-20

Kumar, Shailendra (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C564S199000

Reexamination Certificate

active

10483533

ABSTRACT:
In one aspect, the invention provides a process for the preparation of a compound of Formula Iwherein G is alkyl or aryl, by employing a novel halo-substituted active methylene compound of Formula IIIwherein X is halogen,and process of preparation thereof.

REFERENCES:
patent: 5124482 (1992-06-01), Butler et al.
patent: 5216174 (1993-06-01), Butler et al.
patent: 6274740 (2001-08-01), Lin et al.
patent: 6388093 (2002-05-01), Chamberlain et al.
patent: 6528661 (2003-03-01), Niddam et al.
patent: 2002/0099224 (2002-07-01), Niddam et al.
patent: 2003/0114685 (2003-06-01), Niddam-Hildesheim et al.
patent: 2003/0175338 (2003-09-01), Singh et al.
patent: WO 97/03960 (1997-02-01), None
patent: WO 02/43667 (2002-06-01), None
patent: WO 03/004450 (2003-01-01), None
patent: WO 03/004455 (2003-01-01), None
patent: WO03/004456 (2003-01-01), None
patent: WO 03/016317 (2003-02-01), None
Davis et al, J. Org. Chem., 1995, vol. 60, pp. 4730-4737.
Korinek et al, Coll. Czech. Chem. Comm., vol. 44, 1460-1467, 1979.
International Search Report for corresponding PCT application PCT/IN03/00216, 2003.
Oehrlein R et al., “Chemoenzymatic approach to statin side-chain building blocks” Advanced Synthesis Catalysis (2003), 345 (6+7), 713-715.
Woó et al., “Atorvastatin, an HMG-CoA reductase inhibitor and effective lipid-regulating agent. Part III. Syntheses of [2H5]-,[13C8], and [13C7, 15N] atorvastatin and their application in metabolic and pharmacokinetic studies”, Journal of Labeled Compounds Radiopharmaceuticals (1999), 42(2), 135-145.
Lee et al., “Atorvastatin, an HMG-CoA reductase inhibitor and effective lipid-regulating agent. Part II. Synthesis of side chain-labeled [14C] atorvastatin”, Journal of Labeled Compounds Radiopharmaceuticals (1999), 42(2), 129-133.
Woo et al., “Atorvastatin, an HMG-CoA reductase inhibitor and effective lipid-regulating agent. Part I. Synthesis of ring-labeled [14C] atorvastatin”, Journal of Labeled Compounds Radiopharmaceuticals (1999), 42(2), 121-127.
Radl et al., “An improved synthesis of 1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for atorvastatin synthesis”, Tetrahedron Letters (2002), 43(11), 2087-2090.
Manzoni et al., “Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs”, Applied Microbiology and Biotechnology (2002), 58(5), 555-564.
Roth, Bruce D., “The discovery and development of atorvastatin, a potent novel hypolipidemic agent”, Progess in Medicinal Chemistry (2002), 40, 1-22.
Wierzbicki, Anthony S., “Atorvastatin”, Expert Opinion on Pharmacotherapy (2001), 2(5), 819-830.
Graul et al., “Atorvastatin calcium”, Drugs of the future (1997), 22(9), 956-968.
Baumann et al., “The convergent synthesis of CI-981, an optically active, highly potent, tissue-selective inhibitor of HMG-CoA reductase”, Tetrahedron Letters (1992), 33(17), 2283-2284.

Affiliated with

Also associated with

Rating

Halo-substituted active methylene compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Halo-substituted active methylene compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Halo-substituted active methylene compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3871133